These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 1280849)

  • 1. Serum amyloid P and related molecules associated with the acute-phase response in Alzheimer's disease.
    Kalaria RN
    Res Immunol; 1992; 143(6):637-41. PubMed ID: 1280849
    [No Abstract]   [Full Text] [Related]  

  • 2. Amyloid P component and other acute-phase proteins associated with cerebellar A beta-deposits in Alzheimer's disease.
    Kalaria RN; Perry G
    Brain Res; 1993 Dec; 631(1):151-5. PubMed ID: 7507788
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proteoglycans and the acute-phase response in Alzheimer's disease brain.
    Leveugle B; Fillit H
    Mol Neurobiol; 1994; 9(1-3):25-32. PubMed ID: 7888102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute phase proteins are present in amorphous plaques in the cerebral but not in the cerebellar cortex of patients with Alzheimer's disease.
    Rozemuller JM; Stam FC; Eikelenboom P
    Neurosci Lett; 1990 Oct; 119(1):75-8. PubMed ID: 1711182
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is amyloidogenesis during Alzheimer's disease due to an IL-1-/IL-6-mediated 'acute phase response' in the brain?
    Vandenabeele P; Fiers W
    Immunol Today; 1991 Jul; 12(7):217-9. PubMed ID: 1909530
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum amyloid P in Alzheimer's disease. Implications for dysfunction of the blood-brain barrier.
    Kalaria RN; Golde TE; Cohen ML; Younkin SG
    Ann N Y Acad Sci; 1991; 640():145-8. PubMed ID: 1776732
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Isolation and characterization of amyloid P component from Alzheimer's disease and other types of cerebral amyloidosis.
    Coria F; Castaño E; Prelli F; Larrondo-Lillo M; van Duinen S; Shelanski ML; Frangione B
    Lab Invest; 1988 Apr; 58(4):454-8. PubMed ID: 2965774
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Novel therapeutic approach to amyloidosis: no implications as yet for patients with Alzheimer's disease].
    Lemstra AW; Eikelenboom P; Meijer EW; van Gool WA
    Ned Tijdschr Geneeskd; 2002 Sep; 146(37):1720-3. PubMed ID: 12357871
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The importance of inflammatory mechanisms for the development of Alzheimer's disease.
    Eikelenboom P; Veerhuis R
    Exp Gerontol; 1999 Jun; 34(3):453-61. PubMed ID: 10433400
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The involvement of proteases, protease inhibitors, and an acute phase response in Alzheimer's disease.
    Potter H; Nelson RB; Das S; Siman R; Kayyali US; Dressler D
    Ann N Y Acad Sci; 1992 Dec; 674():161-73. PubMed ID: 1288361
    [No Abstract]   [Full Text] [Related]  

  • 11. Widespread serum amyloid P immunoreactivity in cortical amyloid deposits and the neurofibrillary pathology of Alzheimer's disease and other degenerative disorders.
    Kalaria RN; Galloway PG; Perry G
    Neuropathol Appl Neurobiol; 1991 Jun; 17(3):189-201. PubMed ID: 1891063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pentraxins and Alzheimer's disease: at the interface between biomarkers and pharmacological targets.
    Osera C; Pascale A; Amadio M; Venturini L; Govoni S; Ricevuti G
    Ageing Res Rev; 2012 Apr; 11(2):189-98. PubMed ID: 22186030
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunodetection of the amyloid P component in Alzheimer's disease.
    Duong T; Pommier EC; Scheibel AB
    Acta Neuropathol; 1989; 78(4):429-37. PubMed ID: 2551124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Atherogenesis and the acute-phase reaction of the liver].
    Nagornev VA; Nazarov PG; Polevshchikov VA; Rabinovich VS; Kositskaia LS; Vasil'eva LE; Pigarevskiĭ PV
    Arkh Patol; 1998; 60(6):62-8. PubMed ID: 9949910
    [TBL] [Abstract][Full Text] [Related]  

  • 15. beta-Amyloid vasoactivity in Alzheimer's disease.
    Gurwitz D
    Lancet; 1996 May; 347(9013):1492. PubMed ID: 8676666
    [No Abstract]   [Full Text] [Related]  

  • 16. Concentration of serum amyloid P component in the CSF as a possible marker of cerebral amyloid deposits in Alzheimer's disease.
    Hawkins PN; Rossor MN; Gallimore JR; Miller B; Moore EG; Pepys MB
    Biochem Biophys Res Commun; 1994 Jun; 201(2):722-6. PubMed ID: 7516157
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Microtubule-associated proteins tau and amyloid P component in Alzheimer's disease.
    Duong T; Doucette T; Zidenberg NA; Jacobs RW; Scheibel AB
    Brain Res; 1993 Feb; 603(1):74-86. PubMed ID: 7680941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amyloidosis: new strategies for treatment.
    Hirschfield GM; Hawkins PN
    Int J Biochem Cell Biol; 2003 Dec; 35(12):1608-13. PubMed ID: 12962700
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of acute phase proteins on clearance of chromatin from the circulation of normal mice.
    Burlingame RW; Volzer MA; Harris J; Du Clos TW
    J Immunol; 1996 Jun; 156(12):4783-8. PubMed ID: 8648125
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Coordinated proteomic signature changes in immune response and complement proteins in acute myocardial infarction: the implication of serum amyloid P-component.
    Cubedo J; Padró T; Badimon L
    Int J Cardiol; 2013 Oct; 168(6):5196-204. PubMed ID: 23992930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.